Thursday, April 02, 2020 2:07:09 PM
Evaluating potential for reduction of secondary bacterial infections and mechanical ventilation days to improve patient outcomes and optimize use of scarce ventilators
N8 Medical, LLC Logo (PRNewsfoto/N8 Medical, LLC)
NEWS PROVIDED BY
N8 Medical, LLC
Apr 02, 2020, 09:55 ET
DUBLIN, Ohio, April 2, 2020 /PRNewswire/ -- N8 Medical, LLC (N8 Medical) today announced that Health Canada has granted Dr. John Muscedere of Kingston General Hospital's emergency request to begin using the N8 Medical CeraShield™ Endotracheal Tubes in mechanically-ventilated COVID-19 patients.
N8 Medical's CeraShield™ Endotracheal Tube has a patented anti-fouling coating that is designed to prevent deadly bacterial infections that frequently occur in ventilated patients with respiratory viral infections. In contrast, conventional endotracheal tubes allow pathogenic bacteria to grow on the tube surfaces within hours and form slime-like aggregations of millions of pathogenic cells as a biofilm. In the 1918 influenza pandemic, 95% of influenza patient deaths were caused by secondary bacterial infections. Bacterial infections are a major source of mortality among ICU patients. According to recently published reports, the mortality in COVID-19 patients requiring advanced respiratory support (ventilators) ranges from 66% to 86%. N8 Medical believes that use of the CeraShield™ Endotracheal Tube may reduce this rate of mortality.
"Biofilm growth on endotracheal tubes may lead to deadly secondary bacterial infections and exaggerated inflammatory responses requiring 8 to 9 days of additional mechanical ventilation. Preventing virally-infected patient exposure to bacterial biofilms on the endotracheal tube is critically important," said Carl Genberg, N8 Medical's Chief Scientific Officer. "In a time of severe shortage of mechanical ventilators, we believe that use of the CeraShield™ Endotracheal Tube has the potential to both reduce mortality and optimize ventilator capacity by getting patients off the ventilator sooner. We thank Dr. Muscedere for his efforts to secure use of the CeraShield™ Endotracheal Tube and the Canadian Government for granting his emergency request," said Carl Genberg, N8 Medical's Chief Scientific Officer.
Frost & Sullivan recently issued its Product Innovation of the Year Award to N8 Medical for its platform technology designed to prevent hospital acquired infections. FDA has designated the CeraShield™ Endotracheal Tube as a "breakthrough device" pursuant to the 21st Century Cures Act. The device is currently an investigational product.
Dr Muscedere is an Intensivist at Kingston General Hospital, and Co-Chair of the Canadian Critical Care Trials Group (CCCTG) Knowledge Translation Committee. Dr. Muscedere was the Principal Investigator in a clinical feasibility study of the CeraShield™ Endotracheal Tube of ten patients at Kingston General who were intubated with the CeraShield™ Endotracheal Tube. That study indicated that use of the CeraShield™ Endotracheal Tube does not have adverse side effects and was able to prevent dangerous pathogenic bacteria from growing on the tube and in endotracheal tube aspirates.
N8 medical is currently in discussions with other physicians regarding emergency use during this ventilator resource-straining pandemic.
ABOUT N8 MEDICAL
N8 Medical, LLC (www.N8Medical.com), headquartered in Dublin, Ohio, is a rapidly-growing, privately-held biotechnology company developing a platform of anti-fouling medical devices designed to have significant, life-saving clinical impact through reduction of infection, related complications and mortality. N8 Medical's CeraShield™ technology is based upon novel compounds called ceragenins (also referred to as CSAs). There are over 90 peer-reviewed journal articles regarding the ceragenin technology, which was invented by Professor Paul B. Savage, Professor of Chemistry and Biochemistry at Brigham Young University (Provo, UT). Key publications are available at www.N8Medical.com.
CAUTION: In Canada and the United States, the CeraShield™ Endotracheal Tube and has not been granted marketing approval. These statements have not been evaluated by Health Canada or FDA.
SOURCE N8 Medical, LLC
Related Links
http://www.n8medical.com
"Our houses are such unwieldy property that we are often imprisoned rather than housed in them." - Henry David Thoreau, Walden: Economy, 1854
Recent HYDI News
- Hydromer, Inc. Announces Preliminary Unaudited Second Quarter 2024 Financial Results and Provides Business Update • InvestorsHub NewsWire • 08/07/2024 12:52:38 PM
- Hydromer Announces Attainment of ISO 13485 Certification • InvestorsHub NewsWire • 06/17/2024 01:22:57 PM
- Hydromer Announces Launch of HydroThrombX Medical Device Coating Technology • InvestorsHub NewsWire • 06/05/2024 02:24:00 PM
- Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • InvestorsHub NewsWire • 04/29/2024 01:10:23 PM
- Hydromer, Inc. Wraps Up a Successful 2023, Including Restructuring, Contract Extensions, and the Launch of New Innovations • InvestorsHub NewsWire • 01/16/2024 09:07:55 PM
- Hydromer, Inc. Unveils Rebranding Initiatives Reflecting Its Transformation and Focus on Growth and Innovation • InvestorsHub NewsWire • 12/13/2023 02:44:12 PM
- Hydromer Inc. Announces Formation of its Scientific Advisory Board with the Appointment of its First Member Eric Becktel • InvestorsHub NewsWire • 10/24/2023 01:48:33 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM